(AGTC) |
| 0 (0%) 01-13 20:29 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.49 |
| Resistance 1: | 0.42 |
| Pivot price: | 0.39 |
| Support 1: | 0.38 |
| Support 2: | 0.36 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -64660000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -22.152 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -20.00 |
| Return on Assets (ttm) | 361.5 |
| Return on Equity (ttm) | -42.7 |
Company news
Thu, 08 Jan 2026
Biogen walks away from billion-dollar deal after poor readout - The Pharma Letter
Thu, 24 Apr 2025
Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data from its Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) - PR Newswire
Tue, 28 Jan 2025
Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for laru-zova (AGTC-501) - PR Newswire
Wed, 12 Jun 2024
Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501 - Ophthalmology Times
Tue, 20 Feb 2024
AgTC and AgETL: open-source tools to enhance data collection and management for plant science research - Frontiers
Tue, 13 Jun 2023
Beacon Therapeutics enters gene therapy arena with $120m launch - Pharmaceutical Technology
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
